In short, the development signals that more deals could be on the horizon — particularly in Canada. New York-based Constellation Brands — which owns, distributes and markets beer, wine and spirits brands, including Corona and Robert Mondavi — will acquire 9. Those plans go into a much higher gear today. As medical cannabis continues to gain mainstream adoption, it could impact pharma companies to get involved.
Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of press some accurate, some scrambled. And I also feel sure that advances in this area could lead to many profound medical, social, and economic effects.
GSK, though, is going after diabetes first with the Sirtris deal, I should add — among other reasons, the FDA has no regulatory framework whatsoever for an antigeronic, if I can coin a word.
But whatever the state of the anti-aging field, doubts have crept in about the wisdom of the Sirtris purchase. Now a group at Pfizer has piled on in the Journal of Biological Chemistry. And unfortunately, they also find trouble due to fluorogenic peptides. While the Sirtris compounds looked like activators initially, switching to the native peptide substrates showed them to be worthless.
Further study calorimetry showed that the activator compounds bind to a complex of SIRT1 and the fluorescent peptide substrate, but not to SIRT1 itself or in the presence of native substrate without the fluorogenic group. But worse is to come: We therefore attempted to reproduce the in vivo efficacy for SRT in mouse models of type 2 diabetes previously shown.
The reported high dose of the compound mpk resulted in weight effects and death. The reported low dose 30 mpk showed no effects at all on any diabetic parameters, but instead seemed to lead to increased feeding and weight gain.
Basically, these folks have thrown down the gauntlet: So what is GSK going to have to say about this?Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.
For the treatment of human diseases, nasal and pulmonary routes of drug delivery are gaining increasing importance. Back in the summer, I got the call that no biotech venture investor wants to get.
On the morning of August 8 th, I received an urgent text of “can you talk now?” quickly followed with a call.I learned then of very troubling news regarding a major preclinical safety concern, a “tox signal” in industry parlance, in one of our lead programs.
Implementation Of Quality Risk Management (QRM) In Pharma Industry initiativeblog.com 97 | Page change in product process or formulation / change in critical process parameter or change in any other system directly impacting the quality of .
Implementation Of Quality Risk Management (QRM) In Pharma Industry initiativeblog.com 97 | Page change in product process or formulation / change in critical process parameter or change in any other system directly impacting the quality of product.
Corvidia was founded based on the discovery of genomic determinants of inflammatory risk in cardiac and renal patients. Seeded by Sofinnova Partners in , Corvidia raised $26 Million in an A Series financing round from Sofinnova Partners and Apple Tree Partners. The paper titled “Risk-based Methodology for Validation of Pharmaceutical Batch Processes” describes a statistically sound methodology for determining when a statistically valid number of validation runs has been acquired based on risk assessment and calculation of process capability.